Skip to main content
Roy Chemaly, MD, Infectious Disease, Houston, TX, University of Texas M.D. Anderson Cancer Center

RoyF.ChemalyMD

Infectious Disease • Houston, TX

Professor of Medicine, University Tex MD Anderson Cnacer Center, Houston

Join to view full profile

Dr. Chemaly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chemaly's full profile

Already have an account?

Summary

  • Roy Chemaly, MD, MPH, CMQ. Professor. Chief Infection Control Officer and Director of the Clinical Virology Research program. Dr. Chemaly’s interest include studies on the epidemiology, severity, prognosis, prevention and treatment of respiratory viral infections in immunocompromised cancer patients as well in the prevention of health care associated infections. Dr. Chemaly conducts clinical trials for the management and prevention of viral infections in cancer patients, Hematopoietic Cell Transplant (HCT) recipients, in particular, as well as on the composition of the upper respiratory tract microbiome as a risk factor for lower respiratory tract infections. He is also conducting clinical trials using CMV specific immuno-assays to predict CMV reactivation or progression. In addition, Dr. Chemaly and his lab team are conducting studies on whole genome sequencing for VRE, phages, and CMV to establish the transmission networks and the resistance and virulence genes associated with worse outcomes, respectively. His work in viral infections in HCT recipients has led to landmark publications in high impact journals like New England Journal of Medicine, Annals of Internal Medicine, Blood, and Clinical Infectious Diseases. He is the founder and past chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplantation and a member of the writing committee of the ASBMT guidelines for transplant infectious diseases, and the European Committee for Infections in Leukemia (ECIL 8). He is the co-chair of the Infection & Immune Reconstitution Working Committee of the ASTCT/CIBMTR, an executive member on the council for the International Immunocompromised Host Society (ICHS), and the scientific officer for the working group on respiratory viruses (ESGREV) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). Funding sources: NCI/NIH, NIH subcontracts, Private industry, Institutional Awards.

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Infectious Disease, 1998 - 2001
  • Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital
    Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 1994 - 1998
  • St Joseph's University Medical School
    St Joseph's University Medical SchoolClass of 1992

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2002 - 2025
  • NY State Medical License
    NY State Medical License 1997 - 2003
  • OH State Medical License
    OH State Medical License 2000 - 2003
  • American Board of Pathology Medical Microbiology

Awards, Honors, & Recognition

  • Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients  
    Roy F Chemaly, Elizabeth Shpall, The Journal of Infectious Diseases
  • Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplantation Recipients  
    Samuel L Aitken, Roy F Chemaly, Clinical Infectious Diseases
  • Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials  
    Roy F Chemaly, Kathleen M Mullane, Robin Avery, Raymund R Razonable, Clinical Infectious Diseases
  • Join now to see all

Abstracts/Posters

  • Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
    Roy Chemaly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • A Systematic and Critical Review of Bacteriophage Therapy Against Multi-Drug Resistant ESKAPE Organisms in Humans 
    The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 9/4/2012

Press Mentions

  • 4 Questions About COVID-19 Vaccines and Bivalent Boosters, Answered
    4 Questions About COVID-19 Vaccines and Bivalent Boosters, AnsweredSeptember 22nd, 2022
  • COVID-19’s BA.4 and BA.5 Omicron Subvariants: 12 Questions, Answered
    COVID-19’s BA.4 and BA.5 Omicron Subvariants: 12 Questions, AnsweredJuly 14th, 2022
  • Monkeypox 101: Insights for Cancer Patients and Caregivers
    Monkeypox 101: Insights for Cancer Patients and CaregiversJune 29th, 2022
  • Join now to see all

Hospital Affiliations

Dr. Roy Chemaly, Dr. Roy Chemaly, MD, Dr. R Chemaly, Dr. Roy F. Chemaly